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ABSTRACT
Introduction For couples undergoing assisted reproduction, 
a plethora of adjuncts are available; these are known as 
‘add- ons’. Most add- ons are not supported by good quality 
randomised trial evidence of efficacy, with some proven to 
be ineffective. However, estimates suggest that over 70% of 
fertility clinics provide at least one add- on, often at extra cost 
to the patient. This study has three aims. First, to undertake a 
survey of in vitro fertilisation (IVF) clinics in the UK to ascertain 
which add- ons are being offered and at what cost. Second, to 
undertake qualitative semi- structured interviews of patients, 
clinicians and embryologists, to explore their opinions and 
beliefs surrounding add- ons. Third, to review the interpretation 
of the Human Fertilisation and Embryology Authority traffic light 
system, to better understand the information required by IVF 
patients, clinicians and embryologists when making decisions 
about add- ons.
Methods and analysis All UK IVF clinics will be contacted 
by email and invited to complete an online survey. The survey 
will ask them which add- ons they offer, at what cost per cycle 
and how information is shared with patients. Semi- structured 
interviews will be conducted in the UK and Australia with three 
groups of participants: (i) fertility patients; (ii) clinicians and (iii) 
embryologists. Participants for the interviews will be recruited 
via social media channels, website adverts, email and snowball 
sampling. Up to 20 participants will be recruited for each 
group in each country. Following an online consent process, 
interviews will be conducted via video- conferencing software, 
transcribed verbatim and data subjected to inductive thematic 
analysis.
Ethics and dissemination Ethical approval has been 
granted by the Universities of Sheffield, Bath Spa and 
Melbourne. Findings will be published in a peer- reviewed 
journal and disseminated to regulatory bodies in the UK 
and Australia. A lay summary of findings will be shared via 
Fertility Network, UK.
INTRODUCTION
Undergoing fertility treatment can involve 
physical, mental and financial stress, with 
patients often desperate to explore any 
options which might confer greater chance 
of treatment success. Over recent years 
there has been an increase in medical and 
non- medical in vitro fertilisation (IVF) treat-
ment adjuncts available; these are commonly 
known as ‘add- ons’.1
The UK regulatory body for assisted repro-
duction, Human Fertilisation and Embry-
ology Authority (HFEA) describes add- ons 
as ‘optional extras you may be offered on 
top of your normal fertility treatment, often 
at an additional cost. They’re sometimes 
emerging techniques that may have shown 
some promising results in initial studies, or 
they may have been around for a number of 
years, but haven’t necessarily been proven to 
improve pregnancy or birth rates’.2 In some 
Strengths and limitations of this study
 ► VALUE is the first study to explore, through in- depth, 
semi- structured qualitative interviews, the driving 
factors behind the use of in vitro fertilisation add- 
ons by patients, clinicians and embryologists.
 ► Early and in- depth patient and public involvement 
was used to ensure the study’s acceptability, use 
and relevance to the target population.
 ► Purposive sampling in two different healthcare sys-
tems, encompassing both private and state fund-
ed fertility services will be conducted to capture a 
wide range of patient, clinician and embryologist 
experiences.
 ► We will mitigate the risk that interviewees adjust 
their responses in light of interviewers being med-
ical professionals working in fertility, by training 
interviewers and highlighting their neutrality at the 
start of the interview.
 ► Recruitment via social media may limit the recruit-
ment to a particularly motivated, engaged and me-
dia literate group of participants.
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cases, add- ons have become ‘routine practice’, with costs 
embedded into the fertility package fee as opposed to 
being charged in addition. For example, embryo incu-
bation using time- lapse technology is routine in some 
centres, and is optional in others.3
Assisted reproduction is a fast- paced area of medicine, 
with growing demand for treatment, accompanied by 
rapid innovation.4 There is growing recognition from 
the assisted reproduction community of the paucity 
of evidence surrounding the use of add- ons, most add- 
ons are not supported by good quality randomised trial 
evidence.2 4 5 There has been much speculation and 
interest in the driving forces behind add- ons’ popularity, 
both factors of supply (IVF clinics offering or advertising 
add- ons) and demand (IVF patients requesting add- 
ons).6–9 However, thus far, there has been no research 
specifically focused on why patients, clinicians and 
embryologists opt to offer or use them. There is a lack 
of research into the views of these groups, particularly 
surrounding their interpretation of evidence of efficacy 
of add- ons, and information sources for decision- making 
about their use.
The HFEA have provided a website designed for 
patients regarding add- ons, with a traffic light rating of 
red, amber and green to denote the quality of evidence 
on efficacy and safety of use. However, there is little infor-
mation about the utility of this system, and how patients 
interpret the different traffic light colours. For patients 
in Australia, there is no such similar patient directed 
website.
The practice of medicine rests open three main prin-
ciples of ethics. First beneficence (the moral obligation 
to act for the benefit of others), second non- maleficence 
(requires that medical professionals prevent harm to the 
health and well- being of patients) and third autonomy 
(patients have a right to self- determination, or choices 
in their care). IVF add- ons raise an interesting ethical 
dilemma, given that add- ons have not been conclusively 
proven to make IVF more effective, or reduce the risk of 
harms, such as miscarriage. However, denying a patient’s 
autonomy in opting to use add- ons may also be seen as 
unethical.10 In order for autonomy to be executed, the 
patient must have informed consent, that is, an under-
standing of the potential benefits and risks of any given 
add- on.11
The VALUE study is important because it will help 
inform how patients, clinicians and embryologist 
weigh up the factors that relate to these three pillars 
of medical ethics when thinking about their experience 
of using add- ons. It will also explore what information 
is important to these three stakeholder groups when 
participating in informed consent. It is hoped that the 
information from VALUE will support caregivers to 
provide the best possible ethical care to their patients, 
and improve the quality of the informed consent 
process for patients to better support them in making 
informed decisions.
Aims
This study aims to first undertake a survey of IVF clinics in 
the UK to ascertain which add- ons are being offered and 
at what cost to the patient. Second, through qualitative 
semi- structured individual interviews of assisted repro-
duction patients, clinicians and embryologists, it will then 
explore the opinions and beliefs surrounding add- ons 
and any evidence for efficacy. Finally, the interviews will 
also be used to review the interpretation of information 
provided by regulatory bodies in order to optimise provi-
sion of information for these groups when making future 
decisions about IVF add- ons.
Objectives
1. Provide information on availability of add- ons in UK 
and the costs that are charged for them.
2. To understand how people make decisions about using 
or recommending IVF add- ons.
3. To understand where information about add- ons is 
sought, and to understand the role and importance of 
information such as safety and effectiveness when con-
sidering their use.
4. To explore participants’ understanding and interpre-
tation of the HFEA traffic light system for add- ons.
METHODS AND ANALYSIS
Study design
Part 1: UK clinic survey
A list of all licensed IVF clinics in the UK will be compiled 
using public data from the HFEA website.12 Then, the 
medical director of each clinic will be contacted and 
invited to complete an online survey. The online survey 
will ask the following questions: (i) number of IVF and 
intracytoplasmic sperm injection (ICSI) cycles performed 
in year January 2019–January 2020; (ii) whether the clinic 
treats National Health Service (NHS) and/or private 
privates; (iii) which add- ons they offer at their clinic; (iv) 
the cost per- cycle to patients for the use of each add on; 
(v) whether written information regarding add- ons is 
offered, and the form of this information (ie, published 
by the clinic, or published by Industry) and (vi) whether 
any of the listed add- ons are included as part of an NHS 
funded cycle, or a private cycle (ie, are used routinely). 
The clinic survey is only taking place in the UK because 
a similar survey has already taken place in Australia.13 14
In order to improve the response rates, we will use an 
evidence- based strategy of survey recruitment. A prenoti-
fication email will be sent to the medical director 1 week 
prior to the survey opening outlining the survey and 
informing them that following completion of the survey 
they can choose to be entered into a prize draw for three 
£50 Love2shop vouchers. One week later the link to the 
survey will be emailed with a follow- up email at week 2. 
In week 3 or 4 we will send a further follow- up email and 
phone call to the clinic. In week 6 the survey will close and 
the prize draw winners announced. Those who complete 
the survey will be sent a follow- up email thanking them, 
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and asking if they would be happy to share their patient 
information leaflets on add- ons with us.
Part 2: qualitative in-depth semi- Research Ethics approval was 
not required for the PPI interviews
Interview schedule design
The interview schedule was iteratively developed with 
our patient and public involvement (PPI) group and is 
underpinned by preidentified domains of interest within 
the academic and grey literature: (i) sources of informa-
tion; (ii) the decision- making process and (iii) impor-
tance of evidence. The HFEA 2018 pilot national fertility 
patient survey15 revealed important areas where informa-
tion on add- ons is lacking including where patients seek 
information from, whether information on the efficacy, 
cost- effectiveness and side effects of add- ons is provided. 
Through our semi- structured interview design, we will 
therefore explore participants’ personal experiences in 
deciding whether to use or offer add- ons. We will explore 
factors that are important to them in making this decision 
and their sources of information as well as explore how 
participants in the UK and Australia interpret the HFEA’s 
traffic light system and its role to guiding decision- making 
around add- ons.2
Patient and public involvement
PPI has taken place to tailor the study design to ensure 
it is addressing important research questions and that 
the study materials are presented in a clear and under-
standable format. A ‘study- focussed framework’ will be 
supported, whereby two patients will follow the research 
cycle from initial PPI stages through to disseminating 
findings and achieving impact.16
The PPI process included patients, clinicians and 
embryologists with two PPI groups in both the UK and 
Australia. PPI sessions were conducted separately in the 
UK and Australia due to subtle differences in demo-
graphic questions. Due to concerns about a power 
dynamic between professionals and patients possibly 
preventing participants from feeling able to free express 
themselves17 we held one focus group for patients in each 
location and a separate group for clinicians and embryol-
ogists. Participants were recruited through social media 
and engaged in an hour- long teleconference with other 
panel members and the research team. Each participant 
was provided with a draft set of interview questions ahead 
of the meeting and were asked to comment on them 
during the teleconference. In addition, they were asked 
to review the consent form, the information sheet and the 
study website. A series of questions about the coordina-
tion and practical running of the study were also posed.
The teleconferences were recorded following agree-
ment from participants and followed strict General Data 
Protection Regulation (GDPR) guidance. Participants 
were offered either a £20 love2shop e- voucher or a $50 
Australian supermarket voucher as a thank you for their 
time. All participants consented to being acknowledged 
in resulting publications.
Patients PPI
Two patient participants were sought in each country and 
patients were required to have undergone assisted repro-
duction (IVF or ICSI) in the past 2 years.
As a result of patient PPI, the wording of some of the 
qualitative questions was altered, and prompts were added 
where necessary. The panel felt that the patient interviews 
should be divided in two to enable time for the partici-
pant to browse the HFEA website prior to questions on 
this topic. The feedback was that asking the participant to 
familiarise themselves with the website during the hour- 
long interview was too stressful and would put the partici-
pant under undue pressure. The panel was in agreement 
that two shorter interviews were no more onerous or 
inconvenient than 1- hour long interview. In response to 
feedback, a table of ‘commonly used terms’ was added 
to the preinterview demographic questions (table 1) and 
the website was altered slightly to improve readability.
Embryologists and clinicians PPI
A minimum of two embryologists and two clinicians in 
each country were sought for PPI. Professional data-
bases were checked to ensure that those taking part were 
registered doctors or embryologists delivering fertility 
treatment in the UK or Australia. In the UK, two embry-
ologists and one reproductive medicine specialist doctor 
joined the teleconference, and a separate teleconfer-
ence was undertaken with one other reproductive medi-
cine specialist doctor due to clinical commitments. In 
Australia, one PPI panel was convened, consisting of two 
embryologists and two reproductive medicine specialist 
doctors.
As a result of PPI, the preinterview demographic ques-
tions were altered to accurately reflect clinicians’ job 
titles and questions regarding ethnicity and religion were 
removed. Following panel input, the questions were reor-
dered to improve the flow of the interview and the wording 
of some questions changed to remove any negative conno-
tations towards add- ons. In addition, lay descriptions of 
add- ons were added to the website following feedback 
that this would enable patients to more easily identify 
which add- ons they had used or considered. This panel 
explained that part 1 and part 2 of the interview should 
not be split into two separate interviews for because it was 
too time consuming and may deter clinicians and embry-
ologists from participating. The feedback was that being 
given the chance to look at the HFEA website prior to the 
interview would be preferable to being asked to look at 
it mid- interview. The study protocol has been altered to 
reflect these changes.
VALUE study eligibility criteria
Inclusion criteria
Patients
Adult women, men or couples (18+ years of age); who 
have undergone IVF or ICSI in the past 2 years (any 
number of cycles); publicly funded (NHS funded in the 
UK, or Medicare in Australia) or privately funded; using 
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either autologous oocytes and sperm, or donor oocytes 
and sperm; and who have considered using, or had used, 
one or more add- ons as part of their treatment.
Clinicians
Registered doctors involved in the care of patients or 
couples undergoing assisted reproduction. Doctors 
can be consultant fertility specialists, staff- grade fertility 
specialists or General Practitioners (GPs) who specialise 
in reproductive medicine and work in fertility clinics.
Embryologists
Registered embryologists involved in decisions regarding 
the assessment of embryos, who have direct interaction 
with patients or couples undergoing IVF or ICSI.
Exclusion criteria
Those who are non- fluent English speakers owing to 
the financial cost and logistics of arranging appropriate 
translation assistance during interviews. Those who are 
donating oocytes or sperm therefore undergoing assisted 
reproduction themselves.
Recruitment
In both countries, patient participants will be recruited 
via broad ranging social media advertising, including the 
websites and social media of patient support groups such 
as Fertility Network in the UK. Recruiting participants 
in this way aims to include those from a diverse range of 
socioeconomic and ethnic backgrounds and geographic 
locations. Additionally, this approach should include 
patients or couples who are at varying stages of their IVF 
experience, including those undergoing their first cycle, 
to those embarking on repeated cycles and those who 
have and have not experienced success from IVF.
Clinicians and embryologists will also be recruited 
via websites, newsletters and social media, but in this 
case with the assistance of professional bodies such The 
British Fertility Society and the Association of Reproduc-
tive and Clinical Scientists in the UK. The Fertility Society 
of Australia (FSA) will advertise the study in Australia. 
Recruiting in this manner enables sampling from a broad 
geographical range of clinicians and embryologists, 
working in different clinics, with difference practices.
Both patient participants and professionals may also 
be recruited using a snowballing technique, where at 
the end of the interview existing participants are asked 
to nominate others to be approached for participation. 
Snowball sampling is a valid technique for participant 
recruitment in qualitative research and allows researchers 
to reach populations who otherwise would have been 
hard to reach.
Interested participants in both the UK and Australia 
will be directed to the VALUE study website ( www. value-
study. org) where they can express interest in the study 
using the ‘contact us’ form embedded in the ‘patient’ 
webpage ( www. valuestudy. org/ for- patients) and the 
‘professionals’ webpage ( www. valuestudy. org/ for- profes-
sionals). Researchers will then confirm eligibility and 
obtain informed consent via a secure online form, and 
schedule a time to undertake the interview (figure 1). A 
list of examples of add- ons is provided on the website, and 
has been published as online supplemental table 1.
Sampling strategy and size
Approximately 60 interviews will be conducted in both 
the UK and Australia (20 per participant group) and the 
collection and analysis of data will be done iteratively to 
consider when sufficiently robust codes and themes have 
been created.18 A sample of n=20 per group has been 
based on similar studies,18–22 however, it is recognised 
that deep analysis is more important than number of 
interviews and sample size will be determined by data 
Table 1 Table of commonly used terms
Term we use What it stands for Description of term
IVF In vitro fertilisation The process of stimulating the woman’s ovaries, collection of eggs, mixing of egg/s 
with sperm to make embryos, incubation of embryos and replacement of embryos 
into the woman.
ICSI Intracytoplastic sperm 
injection
The process described above, except instead of mixing the woman’s eggs with 
sperm, a single sperm is selected to be injected into the egg.
A cycle of IVF 
or ICSI
  One cycle of IVF or ICSI includes all the steps involved in IVF or ICSI described 
above, plus the replacement of any resulting embryos from that cycle (fresh or frozen 
transfer). A cancelled cycle, or a cycle where no embryos can be transferred both 
count as a cycle.
Embryo transfer   Embryo transfer refers to the process of replacing an embryo that results from an 
IVF or ICSI cycle. Embryo transfers can be single, where one embryo is transferred, 
or double, where two embryos are transferred. No matter how many embryos are 
replaced, these all count as one embryo transfer procedure.
Ovulation 
induction
  The process of stimulating the ovaries to release an egg each month. This can be 
done using tablets such as clomiphene citrate, or injections. The couple conceive the 
baby through sexual intercourse.
ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilisation.
 on S
eptem









pen: first published as 10.1136/bm





5Armstrong SC, et al. BMJ Open 2021;11:e047307. doi:10.1136/bmjopen-2020-047307
Open access
saturation when no further themes are generated.23 
Couples who wish to be interviewed together will be 
considered as n=1 towards the sample size, however, if 
they wish to be interviewed separately, then they will be 
considered as two participants.
There will be purposive sampling within our inclusion 
criteria, to provide a variety of participants so that readers 
can assess transferability to a wider population of clini-
cians, embryologists and patients undergoing IVF.23 The 
VALUE study aims to interview patients who have had 
government subsidised as well as privately funded cycles. 
It also aims to interview clinicians and embryologists 
working in the public and private sector and to include 
both senior and junior staff, the importance of which was 
highlighted by the PPI panel. Timely thematic analysis of 
the first 20 interviews will be undertaken and if an appro-
priate spread of patients and professionals has not been 
included, we will use a sampling framework for maximum 
variation for the next 20 interviews prior to consent stage 
(table 2).
There will be complete transparency with potential 
participants that we may not need to interview them 
depending on their answers, but that we appreciate their 




•Interested participants directed to www.valuestudy.org from Twitter/email/advert.
Expression of 
interest
•Interested participants can express interest via www.valuestudy.org. Research team 
alerted via email.
Recruitment
•Research team contact potential participants via email and check eligibility criteria are met.
•If eligible, participants are directed to complete electronic consent form. Link sent via 
email.
Consent
•Research team member confirms consent and standardised welcome email is sent 
containing link to demographic questionnaire.




•Participant thanked for their time verbally. Standardised follow up email sent that thanks 
participants, contains £30/$50 e-voucher, and the PDF 'debrief sheet'.
Figure 1 Flow of participants through the VALUE study.
Table 2 Framework sampling questions
Question Patients Professionals
Targeted questions to be asked prior to consent for potential interviewees if analysis of the first 10 interviews is suggestive of 
lack of diverse respondents.
1 Please can we ask how many cycles 
of IVF or ICSI you have undergone?
Please can you share your clinical title?
2 Please can we ask whether you have 
received NHS funded or privately 
funded IVF or ICSI? Perhaps you 
have had both?
How many years have you worked in the discipline of reproductive 
medicine? (clinicians only)
3   Please can we ask whether you see and treat NHS funded or privately 
funded IVF or ICSI? Perhaps you treat had both? Please can you explain.
ICSI, Intracytoplasmic sperm injection; IVF, in vitro fertilisation; NHS, National Health Service.
 on S
eptem









pen: first published as 10.1136/bm





6 Armstrong SC, et al. BMJ Open 2021;11:e047307. doi:10.1136/bmjopen-2020-047307
Open access 
their answers to these questions will not be recorded as 
part of the study.
Interviews
Interviews will be held remotely using video- conferencing 
software and will be recorded to aid transcription. Patients 
will be interviewed twice. First with nine questions, lasting 
approximately 45 min, following this they will be asked to 
review the HFEA website prior to the second interview of 
eight questions, lasting approximately 30 min. Clinicians 
and embryologists will participate in a single interview 
of approximately 60 min interview containing 15 ques-
tions. Interview schedule will not be made available until 
after all interviews have been conducted so as not bias 
responses from participants having seen the questions in 
advance of the interviews from this publication. However, 
they will be available on request after the interviews have 
been completed.
The interview will be conducted by members of 
the research team who have undergone training in 
conducting semi- structured interviews about potentially 
upsetting topics. At the beginning of the interview partici-
pants will be asked to try to avoid mentioning their names 
or those of IVF clinics or staff; although, the onus will be 
on the research team to fully anonymise subsequent tran-
scriptions. Participants will be reminded that involvement 
in the research is entirely voluntary and that they can 
withdraw at any point during the interview. For clinicians 
and embryologists, they will be reminded prior to the 
interview that it is not a test of their clinical knowledge 
and that all information shared will be kept confidential.
Patients, clinicians and embryologists will be offered a 
£30 e- Gift Card for love2shop or a $50 Australian super-
market voucher as a thank you for their time. National 
Institute for Health Research recommend rewarding 
public participation in research and vouchers of this 
value are an appropriate thank you for their time.24
Transcription
Audio recordings will be kept on secure servers and will 
undergo transcription by a third- party confidential and 
secure password protected transcription service. Tran-
scription of audio recording will be checked by the 
in- country research team to ensure that all identifiably 
data are removed and the transcript deidentified.
Analysis
The clinic survey data and demographic data from inter-
view participants will be exported to a password protected 
Excel spreadsheet and will undergo descriptive analysis.
The interview data will undergo inductive thematic 
analysis to identify descriptive labels (codes) through 
repeated analysis. Codes will be used to group data into 
subthemes and further overarching themes to produce 
a complex account of data that is both rich and detailed 
and appropriate to purpose.25 Thematic analysis covers 
a range of epistemological and ontological decisions; 
we will use it as a ‘contextualist’ method within a critical 
realist paradigm.24 26 Thematic analysis is an appropriate 
framework to use for data collection and analysis as it 
enables a detailed account of data that is both descriptive 
and interpretive.27 It can acknowledge how people make 
sense of their experiences as well as how broad social 
structures interact with these.28 It should enable an over- 
arching understanding of the experience of the three 
groups being interviewed in this study.
Analysis will begin with listening to interview recordings 
and reading each transcript many times to establish famil-
iarity with the whole interview and become immersed 
in the data, noting initial interpretations. Initial codes 
(salient features) will be created, to arrange the data 
into meaningful segments. In the main analytic phase, 
different codes will be reviewed and combined to form 
broader themes. The first set of coding and themes will 
be reflexively considered until consensus is reached to 
define, name and exemplify all themes.
Reducing bias
We acknowledge that some of the authors of this study 
have been involved in the publication of evidence that 
does not support the routine use of IVF add- ons. Every 
effort has been made to be aware of this and mitigate 
it in the planning, execution and analysis of VALUE. 
The interview questions have undergone a robust PPI 
process, and were also subject to close scrutiny by the 
ethical review bodies at the Universities of Sheffield and 
Melbourne. Changes were made to the wording of ques-
tions as a result of feedback from these processes where 
there was felt to be any implied judgement. In addition, 
interviewers have undergone the planned training on 
undertaking qualitative interviews. Furthermore, double 
coding on a proportion of the interview data is being 
undertaken by Dr Wainwright, who was brought into the 
project as someone experienced in PPI and qualitative 
methods but who has not been involved in the publica-
tion of evidence that does not support the routine use of 
IVF add- ons.
Data protection
All data from the VALUE study will be stored securely on 
password protected encrypted servers. No hard copies of 
data will be kept. Demographic data, interview recordings 
and transcripts will be stored in the country of origin (UK 
participants’ data will be stored at the University of Shef-
field, and Australia participants’ data will be stored at the 
University of Melbourne). Only deidentified interview 
transcripts will be shared between the UK and Australia 
sites and uploaded to form part of qualitative analysis on 
using secure password protected analytic application. All 
recordings will be deleted after the transcripts have been 
checked by the respective country’s research team and 
are fully anonymised.
The VALUE study will not release anonymised tran-
scripts for future research. This decision has been made 
in light of the sensitive nature of the topic and in response 
to PPI feedback which suggested that participants may 
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feel inhibited to speak openly due to the nature of their 
stories being potentially identifiable.
Ethics and dissemination
Ethical considerations
Research ethics approval was not required for the PPI 
phase of this study. In the UK, ethical approval has been 
obtained from the University of Sheffield (reference: 
036268) and Bath Spa University (BSU-20-205) and in 
Australia ethical approval has been obtained from Univer-
sity of Melbourne (2057434.1). Participants will receive 
comprehensive information leaflets prior to the study 
and participants will undergo an online written consent 
process prior to interview with all participant information 
treated confidentially. Participants are free to withdraw 
from the study at any time.
Output and dissemination
Results will be published in a peer- review journal and 
disseminated to regulatory bodies such as the HFEA, The 
National Institute for Care and Clinical Excellence, the 
Victorian Assisted Reproduction Treatment Authority 
(Australia) and the FSA in order to help shape future 
information about IVF add- ons. A lay summary of find-
ings will be shared with participants from our PPI panel, 
patients interviewed and via fertility UK to highlight 
results from the work to the wider public.
The VALUE study aims that rich qualitative data from 
this research will help improve communication of clinical 
impact of IVF add- ons to patients in future. It also hopes 
to analyse understanding and interpretability of a traffic 
light system in conveying information to patients and 
professionals, generating information which can be used 
to inform the use of the traffic light system in regulatory 
bodies in other countries.
Limitations
Recruitment via social media aims to facilitate purposive 
sampling of participants from different geographical 
locations, and different socioeconomic backgrounds. 
However, a significant limitation of this approach is that it 
may attract a particularly information technology literate, 
motivated group of individuals. One concern is that 
patient participants who are looking at fertility websites 
and social media outlets, may be more likely to be further 
into their fertility journey, and less likely to be under-
going their first cycle of assisted reproduction. We aim to 
ameliorate this by using a variety of social media outlets, 
plus websites and emails.
Researchers involved in VALUE have been involved in 
novel research that has thrown into question the ratio-
nale of the routine use of some add- ons. This involvement 
in research may be known to some participants, and one 
limitation is the risk that participants may alter their 
responses in light of this. The qualitative interviews have 
been carefully designed to demonstrate equipoise and to 
not introduce any form of value judgement.
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Supplementary Table 1: Table of examples of add-ons 
 
Add-ons for eggs, sperm, embryos 
Egg activation Trying to stimulate egg activation with a substance called calcium 
ionophore which the embryo is treated with. 
Intrauterine culture Fertilising the egg in the lab then transferring the embryo in an 
intrauterine culture device into the womb where it stays for a 
few hours during embryo development. It is then removed and 
the embryo put back in an incubator. 
Embryo Glue EmbryoGlue contains a substance called hyaluronan, which aims 
to improve the chance of the embryo implanting in the womb. 
Elective freeze-all 
cycles 
Creating embryos then freezing them all so none are transferred 
in the 'fresh' cycle. 
Assisted hatching Using acid, lasers or other tools to thin or make a hole in the 
zona pellucida (the layer surrounding an embryo) in order to try 
to help the embryo 'hatch'. 
Preimplantation 
genetic testing (PGT) 
Checking the genes or chromosomes of the embryos for 
abnormalities before deciding which embryo to transfer. 
Sperm DNA test Analysing the DNA in sperm for damage. 




Adding growth factors to the solution used to bathe the 






Using a high-power microscope to look at the sperm to try to 
help with selection of the best sperm prior to ICSI. 
 
SpermSlow A solution containing hyaluronic acid to try and help select the 






A process that enables many images of the developing embryos 
to be taken without removing them from the incubator. It also 
has the ability to help the embryologist decide which is the best 
embryo to replace 
Medications, including tablets and drips 
Intravenous 
immunoglobulin (IVIG) 
A blood product containing antibodies given through a drip to 
try to help the immune system not to reject an embryo. 
Tumour necrosis factor 
alpha blocking agents 
Medicine given either as an injection under the skin or into a 
vein to try help the immune system not to reject an embryo. 
Intralipid infusion Medicine given through a drip to reduce the activity of NK cells 
in the immune system to try to improve IVF outcomes. 
Quad therapy: aspirin, 
heparin, progesterone 
and prednisolone 
A combination of medicines to try to help implantation and the 
early growth of an embryo. 
 
Platelet rich plasma A blood product infused either into the uterus or injected into 
the ovaries to try to improve egg quality or the chance of an 
embryo implanting into the lining of the womb. 
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A hormone given to try to improve the number and quality of 
eggs and embryos. 
 
Procedures 
Endometrial scratching A procedure carried out before IVF where the lining of the 
womb is deliberately scratched to try and make the womb lining 
more receptive to the embryo implanting. 
Endometrial receptivity 
array (ERA) 
A genetic test undertaken from a sample of the lining of the 
womb to try and help with timing of embryo transfer. 
Alternative therapies 
Chinese medicine The use of herbal medicines to try and improve fertility 
treatment outcomes. 
Acupuncture Inserting small needles into the skin at specific places on the 
body to try to improve fertility outcomes. 
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